We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 23 March 2020
Arrhythmia is a potentially fatal side effect of antipsychotics. A biologic predictive tool to prevent it is missing.
Identification of a genetic profile at risk for antipsychotic induced arrhythmia.
Identifying a molecular pathway enriched for antipsychotic induced QT-modifications.
Seven hundred and sixty-five SKZ individuals, M = 556, age = 40.93 ± 11.03 were included. QT-variation was a phase-specific created variable. A nested mixed regression served in R for clinical and molecular pathway analyses. Plink served for genetic analyses. Quality checking was standard, inflation factor was controlled by lambda values.
Quetiapine and Perphenazine were associated with QT variation (P = 0.002; Estimate = 5.79 and P = 5.67e-06; Estimate = 8.96 respectively). No other significant association was detected. No inflation was detected. Axon guidance and Collagen biosynthesis (Table 1) were associated with QT variation at a conservative (adjusted) P value < 0.01.
Two molecular pathways were identified as possibly involved in QT modifications during antispsychotic treatment in SKZ patients. Previous evidence supports a role of the same pathways in cardiac disorders [1,2]. Interaction of specific SNPs with the drugs will be focus of further research.
The authors have not supplied their declaration of competing interest.
Table 1 Molecular pathways enriched in association with QT modifications.
Table 1 Molecular pathways enriched in association with QT modifications.
You have
Access
Comments
No Comments have been published for this article.